Read by QxMD icon Read

Bladder botox

Florie Bottet, Benoit Peyronnet, Romain Boissier, Bénédicte Reiss, Jean G Previnaire, Andrea Manunta, Jacques Kerdraon, Alain Ruffion, Loïc Lenormand, Brigitte Perrouin Verbe, Sarah Gaillet, Xavier Gamé, Gilles Karsenty
AIMS: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). METHODS: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC)...
April 21, 2017: Neurourology and Urodynamics
Rodolfo A Elizondo, Christof Karmonik, Timothy B Boone, Rose Khavari
INTRODUCTION: Multiple sclerosis (MS) is a severe debilitating disease that affects patients' quality of life. Up to 90% of patients with MS will develop lower urinary tract dysfunction within the first 18 years of the disease. If oral pharmacotherapy with anticholinergics, behavioural modifications and pelvic floor physical therapy are unsuccessful, intradetrusor injection of botulinum toxin-A (OnaBotA; Botox Allergan, Dublin, Ireland) is a highly effective option for these patients...
February 3, 2017: BMJ Open
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
INTRODUCTION AND HYPOTHESIS: Intravesical onabotulinumtoxinA (Botox) injections are effective for the treatment of idiopathic overactive bladder (OAB) symptoms. The aim of our study was to assess the predisposing factors for urinary retention in women with OAB after intravesical Botox injection. METHODS: All participants were women of European descent with idiopathic OAB. OnabotulinumtoxinA (100 U) was administered in 20 intra-detrusor injections. Analysis was performed based on the results of safety assessments made during follow-up (FU) visits on weeks 2, 4 and 12, in 208 women who were treated with Botox injections for refractory OAB and who completed all FU visits...
November 26, 2016: International Urogynecology Journal
Ian Wright, Andrea Civitarese, Richard Baverstock
The use of intra-detrusor onabotulinumtoxinA (Botox(®)) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Ana Claudia Paradella, André Ferraz de Arruda Musegante, Carlos Brites
Intravesical botulinum toxin A (BoNTA) injection has been widely used for the treatment of detrusor overactivity in patients with neurogenic bladder due to spinal cord injury who do not respond to conventional treatment. There is no consensus about antibiotic prophylaxis for this procedure. We conducted a retrospective analysis of medical records of adult patients with spinal cord injury who underwent detrusor BoNTA injection between January of 2007 and December of 2013 in a rehabilitation hospital. Occurrence of symptomatic urinary tract infection (UTI) was assessed in 3 groups in accordance with their use of antibiotics (prophylactic dosage, 3 days, more than 3 days) for the treatment of asymptomatic bacteriuria...
November 2016: Brazilian Journal of Infectious Diseases
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
AIMS: Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire. METHODS: Sixty-eight sexually active women with idiopathic OAB with at least one episode of UUI and ≥8 micturitions per 24 h were recruited...
October 4, 2016: Neurourology and Urodynamics
Laura Weglinski, Rebecca Haddad, Benoit Peyronnet, Xavier Game, Calin Ciofu, Gerard Amarenco
OBJECTIVE: Intradetrusorial injection of botulinum toxin A (IDBT) is a validated treatment for neurogenic and non-neurogenic refractory overactive bladder. In the elderly, muscarinic antagonists have many side effects, in particular in cognition. An alternative treatment is, for that reason, interesting in this frail population with multiple medication use. The question of efficacy is remaining. Indeed, bladder dysfunction is most of the time a multifactorial issue in the elderly. The objective of this study was to evaluate prospectively the efficacy and safety of IDBT in this population...
September 2016: Annals of Physical and Rehabilitation Medicine
I Dominique, A Bourmaud, B Tamarelle, J E Terrier, A Ruffion
INTRODUCTION: Preoperative information before bladder wall injection of botulinum toxin A (Botox(®)) holds several essential facts to understand and retain by the patients. The aim of this study was a review of essential preoperative information items according to GENULF medical experts. METHOD: It was a prospective review from December 2015 to April 2016. Three Delphi rounds had been done from the Survey Monkey(®) software. The initial questionnaire was composed of items from the patient information sheet edited by the GENULF...
December 2016: Progrès en Urologie
(no author information available yet)
In two clinical trials, botulinum toxin injected during cystoscopy transiently prevented urinary incontinence in 1 in 5 patients but sometimes provoked urine retention and urinary tract infections.
March 2016: Prescrire International
Yuh-Chen Kuo, Hann-Chorng Kuo
Intravesical onabotulinumtoxinA (BoNT-A) injections have been proposed to treat both overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS) in patients with refractory conditions. We compared adverse events (AEs) after BoNT-A treatment between IC/BPS and OAB in women. IC/BPS patients who failed conventional treatments were enrolled to receive suburothelial injections of BoNT-A (100 U) followed by hydrodistention. Age matched OAB female patients refractory to antimuscarinic agents underwent BoNT-A (100 U) injections...
March 16, 2016: Toxins
B Lee, N Featherstone, P Nagappan, L McCarthy, S O'Toole
INTRODUCTION: A large number of children with spina bifida develop a neuropathic bladder and this group of patients still forms the largest group of children who require urological management. Although there are published guidelines on the management of the neuropathic bladder, they are not specific to children. It is unsurprising, therefore, that the initial investigation, assessment and management of children with spina bifida vary considerably. The 2014 British Association of Paediatric Urologists (BAPU) meeting was devoted to the management of the neuropathic bladder...
April 2016: Journal of Pediatric Urology
Pawel Miotla, Rufus Cartwright, Konrad Futyma, Michal Bogusiewicz, Katarzyna Skorupska, Izabela Winkler, Tomasz Rechberger
AIMS: Despite the efficacy of intravesical onabotulinumtoxinA (Botox) therapy for urgency, urgency incontinence, and daytime frequency, its value in treatment of nocturia remains unclear. The aim of the prospective observational study was to assess the effect of onabotulinumtoxinA on night-time symptoms in women with overactive bladder (OAB), including nocturia, night-time urgency incontinence, and nocturnal voided volume as end-points. METHODS: Women with idiopathic OAB (with at least one episode of urgency urinary incontinence (UUI) per day, ≥8 micturitions per 24 hr, and ≥2 nocturia episodes per night) were enrolled...
March 2017: Neurourology and Urodynamics
Humberto R Vigil, Duane R Hickling
There is a high incidence of urinary tract infection (UTI) in patients with neurogenic lower urinary tract function. This results in significant morbidity and health care utilization. Multiple well-established risk factors unique to a neurogenic bladder (NB) exist while others require ongoing investigation. It is important for care providers to have a good understanding of the different structural, physiological, immunological and catheter-related risk factors so that they may be modified when possible. Diagnosis remains complicated...
February 2016: Translational Andrology and Urology
Filip Weckx, Manuela Tutolo, Dirk De Ridder, Frank Van der Aa
Neurogenic detrusor overactivity (NDO) can result in lower and upper urinary tract complications and eventually even in end-stage kidney failure. Since the driving force of this clinical cascade is high bladder pressure, controlling intravesical pressure in NDO patients improves both quality of life and life-expectancy in these patients. Botulinum toxin A (BTX-A) has proven its efficacy in reducing intravesical pressure and in reducing incontinence episodes. BTX-A also improves quality of life in patients with NDO...
February 2016: Translational Andrology and Urology
Christopher P Smith, Michael B Chancellor
Alteration in neural control from suprapontine areas to the nerves innervating the bladder can lead to bladder dysfunction and the development of a neurogenic bladder (NGB). Patients with NGB often suffer from urinary incontinence, which can lead to adverse events such as urinary tract infections and decubiti, in addition to creating a large care burden for family members or healthcare providers and significantly impairing patient quality of life. The common failure of anticholinergic medications has spurned the development of second-line treatments, including the use of botulinum toxin...
February 2016: Seminars in Neurology
Sheng-Mou Hsiao, Ho-Hsiung Lin, Hann-Chorng Kuo
OBJECTIVES: To analyze the predictors of therapeutic efficacy after intravesical botulinum toxin A injection for overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. METHODS: All consecutively OAB patients, who visited the urologic outpatient clinics of a medical center and refractory to antimuscarinic treatment, were prospectively enrolled. All enrolled patients received intravesical injection of 100 U onabotulinumtoxinA (Botox). The Global Response Assessment (GRA) score ≥ 2 at 3 months after Botox injection was defined as a successful treatment, otherwise failed...
2016: PloS One
Nagendra Nath Mishra
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease characterized by pelvic pain urgency and frequency. Patients with severe symptoms lead a very miserable life. North American, European and Asian guidelines have been recently promulgated but they differ on many important issues. There is no consensus on its name, definition, investigations and management. Indian guidelines have also been developed and they give more importance to the symptoms in relation to micturition. Though initially believed to be rare or non-existent in India the situation has changed...
October 2015: Translational Andrology and Urology
J M Soler, J G Previnaire, N Hadiji
STUDY DESIGN: This is a retrospective study. OBJECTIVES: The objective of this study was to determine outcome predictors for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia (DSD) in patients with spinal cord injury. METHODS: Botulinum toxin type A (100 Units Botox, Allergan) was injected into the external urethral sphincter using a transperineal approach under EMG guidance. Treatment was indicated if DSD was found on urodynamic testing with a post-void residual volume (PVR) above 100 ml...
June 2016: Spinal Cord
Yih-Chou Chen, Hann-Chorng Kuo
OBJECTIVES: Intravesical injection of onabotulinumtoxinA (i.e. Botox) provides effective treatment for overactive bladder. However, treatment-related adverse events (AEs) remain problems. This study investigated the effect of AEs after onabotulinumtoxinA injection on the success rate for idiopathic detrusor overactivity (IDO). METHODS: A total of 174 patients who received the first single intravesical onabotulinumtoxinA 100U injection for refractory IDO were included...
January 2012: Lower Urinary Tract Symptoms
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"